Clinical Trial News and Research

RSS

Investigational Ebola treatment found to be safe in adults

The investigational Ebola treatment mAb114 is safe, well-tolerated, and easy to administer, according to findings from an early-stage clinical trial published in The Lancet.

25 Jan 2019

Joint patent for use of microbiota replacement therapy to treat gynecological infections

A patent describing the use of 'microbiota replacement therapy' was filed as a joint venture between King's and University College London's Institute of Child Health last month.

25 Jan 2019

Researchers demonstrate strong evidence connecting bacterial pathogen and Alzheimer's pathogenesisis

New science uncovers how an unlikely culprit, Porphyromonas gingivalis (Pg) - the bacterium commonly associated with chronic gum disease - appears to drive Alzheimer's disease (AD) pathology.

24 Jan 2019

CMV vaccine provides a new way to fight malaria

Early research on a new approach to protecting against malaria is offering promising, potentially long-lasting results against the persistent parasite that sickens hundreds of millions people each year.

24 Jan 2019

Clinical testing begins for temperature-stable experimental tuberculosis vaccine

Vaccinations have begun in a Phase 1 human clinical trial testing a freeze-dried, temperature-stable formulation of an experimental tuberculosis vaccine candidate.

23 Jan 2019

Study to investigate new targeted oral treatments for severe asthma

A £2.68 million study to investigate the effective use of antibiotics to treat certain types of severe asthma is being spearheaded by researchers in Leicester.

21 Jan 2019

Mount Sinai joins with Paradigm and ReqMed to repurpose drug for treatment of MPS

The Icahn School of Medicine at Mount Sinai has entered into two exclusive licenses to develop the drug pentosan polysulfate sodium for and ReqMed Company, Ltd. of Japan.

21 Jan 2019

Combination therapy shows high efficacy in treating people with leishmaniasis and HIV

The results of clinical trials conducted in Ethiopia by the Drugs for Neglected Diseases initiative, in partnership with Médecins Sans Frontières, the University of Gondar, and Addis Ababa University, open the way for more effective and safer treatments for people with both HIV and visceral leishmaniasis, a group of patients who have historically suffered from poor treatment options.

18 Jan 2019

New machine learning algorithms identify early symptoms of urinary tract infections

New AI developed at the University of Surrey could identify and help reduce one of the top causes of hospitalization for people living with dementia: urinary tract infections.

17 Jan 2019

OSSIO granted FDA 510(k) market clearance for OSSIOfiber Bone Pin Family

OSSIO, an orthopedic fixation company, today announced that its OSSIOfiber Bone Pin Family has received 510(k) market clearance from the U.S. Food and Drug Administration.

16 Jan 2019

Hypertension drug may improve effectiveness of ovarian cancer treatment

A new study from a Massachusetts General Hospital research team has found that the hypertension drug losartan, which targets the angiotensin signaling pathway, may improve the effectiveness of chemotherapy agents used to treat ovarian cancer

16 Jan 2019

Multiple sclerosis could benefit from stem cell therapy

Patients with relapsing multiple sclerosis (MS) have benefited from an experimental stem cell therapy. MS is an autoimmune disease where the central nervous system is affected. It is severely debilitating and means a slow and progressive death for the patients.

16 Jan 2019

Clinigen, Accord Healthcare extend exclusive European clinical trial supply agreement

Clinigen Group plc, the global pharmaceutical and services company, announces that its Clinical Trial Service business has extended its exclusive European clinical trial supply agreement with Accord Healthcare. Clinigen is also offering pharma companies an ‘on demand’ service to Accord’s products, a first for the industry.

From Clinigen Group 11 Jan 2019

New method modifies blood stem cells to reverse genetic mutation that causes IPEX

UCLA researchers led by Dr. Donald Kohn have created a method for modifying blood stem cells to reverse the genetic mutation that causes a life-threatening autoimmune syndrome called IPEX.

11 Jan 2019

Clinical evidence firmly confirms the HIV Undetectable = Untransmittable concept

In recent years, an overwhelming body of clinical evidence has firmly established the HIV Undetectable = Untransmittable concept as scientifically sound, say officials from the National Institutes of Health.

11 Jan 2019

AGA's new clinical guideline to help manage patients with mild-to-moderate ulcerative colitis

Most patients with ulcerative colitis have mild-to-moderate disease characterized by periods of activity or remission, but practice variations exist in disease management.

10 Jan 2019

Aggressive prostate cancer linked to hereditary breast cancer, confirms study

Aggressive prostate cancer, one of the leading causes of cancer deaths in men, is associated with BRCA2 mutations, which are also linked to hereditary breast cancer, ovarian cancer and pancreas cancer, among others.

10 Jan 2019

Investigational topical cream may be effective for treating atopic dermatitis

A study published in the British Journal of Dermatology indicates that an investigational nonsteroidal topical cream may be effective for treating atopic dermatitis, one of the most common inflammatory skin diseases.

9 Jan 2019

UC San Diego to conduct first U.S. clinical trial of intravenously administered bacteriophage therapy

The U.S. Food and Drug Administration has accepted an Investigational New Drug application by physician-scientists at University of California San Diego School of Medicine to conduct the first U.S. clinical trial of an intravenously administered bacteriophage-based therapy.

9 Jan 2019

FDA approves initiation of first-in-human trial of DNA-encoded monoclonal antibody

The Wistar Institute, along with partners Penn Medicine and Inovio Pharmaceuticals, Inc., announce that the FDA has approved the initiation of a first-in-human clinical trial investigating the safety and tolerability of a novel synthetic DNA-encoded monoclonal antibody therapeutic technology for the prevention of Zika virus infection.

9 Jan 2019

Clinical Trial News and Research

Investigational Ebola treatment found to be safe in adults

Joint patent for use of microbiota replacement therapy to treat gynecological infections

Researchers demonstrate strong evidence connecting bacterial pathogen and Alzheimer's pathogenesisis

CMV vaccine provides a new way to fight malaria

Clinical testing begins for temperature-stable experimental tuberculosis vaccine

Study to investigate new targeted oral treatments for severe asthma

Mount Sinai joins with Paradigm and ReqMed to repurpose drug for treatment of MPS

Combination therapy shows high efficacy in treating people with leishmaniasis and HIV

New machine learning algorithms identify early symptoms of urinary tract infections

OSSIO granted FDA 510(k) market clearance for OSSIOfiber Bone Pin Family

Hypertension drug may improve effectiveness of ovarian cancer treatment

Multiple sclerosis could benefit from stem cell therapy

Clinigen, Accord Healthcare extend exclusive European clinical trial supply agreement

New method modifies blood stem cells to reverse genetic mutation that causes IPEX

Clinical evidence firmly confirms the HIV Undetectable = Untransmittable concept

AGA's new clinical guideline to help manage patients with mild-to-moderate ulcerative colitis

Aggressive prostate cancer linked to hereditary breast cancer, confirms study

Investigational topical cream may be effective for treating atopic dermatitis

UC San Diego to conduct first U.S. clinical trial of intravenously administered bacteriophage therapy

FDA approves initiation of first-in-human trial of DNA-encoded monoclonal antibody

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer